LongevityNext / Trials
Source-reviewed evidence, findings and limitations. Research intelligence, not treatment recommendations.
31 eligible records
Source-reviewed intelligence
Automatically included source-reviewed records; inclusion is not an editorial endorsement.
Evidence reviewed
Clarity AD: CLARITY AD showed less average cognitive-functional decline with lecanemab over 18 months, not recovery, with material ARIA and infusion-reaction risks.
Boundary: Both groups worsened; an 18-month randomized comparison does not demonstrate causal long-term extension benefit.
Evidence reviewed
DO-HEALTH: DO-HEALTH's selected methylation substudy found small omega-3-related changes in PhenoAge, GrimAge2 and DunedinPACE, not proof of clinical rejuvenation or lifespan gain.
Boundary: Clock response does not establish lifespan extension or whole-body rejuvenation.
Evidence reviewed
SELECT: SELECT demonstrated fewer major cardiovascular events with semaglutide in adults with established cardiovascular disease and overweight/obesity without diabetes, alongside greater treatment discontinuation.
Boundary: A secondary composite including macroalbuminuria is not proof of preventing kidney failure in all populations.
Evidence reviewed
PREDIMED: PREDIMED's withdrawn 2013 report must not serve as the current efficacy source; the 2018 replacement is a reanalysis of the same experiment after randomization deviations.
Boundary: The 2013 and 2018 articles cannot be counted as independent replication.
Evidence reviewed
US POINTER: US POINTER found a small additional cognitive-score improvement from structured versus self-guided multidomain lifestyle intervention, not an intervention-versus-inactivity effect.
Boundary: Cognitive-score improvement does not itself establish reduced dementia incidence.
Evidence reviewed
FINGER: FINGER's modest cognitive-score benefit and MAPT's adjusted null comparisons support an intervention-design-specific, not universal multidomain-prevention claim.
Boundary: Cognitive-score improvement does not itself establish reduced dementia incidence.
Source-reviewed intelligence
Directly related records lead this section.
Evidence reviewed
A small randomized crossover mechanistic study in older adults with impaired glucose tolerance.
Boundary: Not clinical longevity-outcome, treatment, prevention or dosing evidence.
Evidence reviewed
A role-based framework for reading trial endpoints, estimands, multiplicity, clinical meaning and surrogate claims.
Boundary: Endpoint labels alone do not establish confirmatory force or clinical importance.
Evidence reviewed
Tracks TAME's proposed design, composite endpoint, funding, registration and launch status without treating plans as results.
Boundary: Design and status are not results; metformin is not established as an anti-aging treatment.
Source-reviewed intelligence
Additional directly related records follow the section-specific lead set.
Evidence reviewed
Separates DO-HEALTH's null primary clinical endpoint family from a later small post hoc DNA-methylation signal.
Boundary: Clock changes are not proof of slower clinical aging, healthspan or lifespan.
Evidence reviewed
A claim-to-evidence framework separating exposure, target engagement, biomarker movement, safety and clinical benefit.
Boundary: Interpretive context does not establish that an intervention works.
Evidence reviewed
The aging Hallmarks are an influential research framework, not a complete causal theory, treatment checklist or validated endpoint set.
Boundary: Framework context does not validate an intervention, biomarker or clinical endpoint.
Evidence reviewed
Company-and-pipeline intelligence separating company reports, registry facts and unavailable clinical outcomes.
Boundary: Pipeline and source mapping, not clinical validation or investment analysis.
Evidence reviewed
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
Evidence reviewed
Separates molecule-specific clinical outcomes from observational, mechanistic and direct longevity claims.
Boundary: Benefits in indicated high-risk populations do not establish direct slowing of aging or lifespan extension in generally healthy people.
Evidence reviewed
Tracks human senolytic evidence, registered programs, negative translation and preclinical limits.
Boundary: Early proof of biology and model clearance do not establish human rejuvenation, generalized healthspan or lifespan extension.
LN Pro preview